Pharmaceutical News and Articles

FDA Approves Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

– Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment  – Multiple authorized treatment centers activated 

Vertex and CRISPR Therapeutics Announce US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Most Americans Lose Sleep Due to 'Digital Distractions.' Experts Offer Tips to Help

It has likely happened to everyone at some point You are poised to go to sleep, but instead a digital distraction keeps you up hours later than you had planned.

CDC: Number of Cantaloupe-Related Salmonella Cases Has Doubled

U.S. health officials reported Thursday that the number of cases of cantaloupe-related Salmonella has doubled. Since the last update on Nov. 30, 2023, an additi

First Gene-Editing Therapies for Sickle Cell Disease Approved by FDA

Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration.Casgevy is the first medicine available in the

Geographic Variability Seen in County-Level Preterm Birth Rates

Considerable geographic variability is seen in county-level preterm birth rates, according to a study published online Dec. 8 in JAMA Network Open.Sadiya S. Kha

Adenotonsillectomy No Aid for Neurodevelopmental Outcomes in Children

In children with mild sleep-disordered breathing (SDB), adenotonsillectomy does not significantly improve executive function or attention, according to a study

SABCS: Outcomes No Worse for Survivors With Less Frequent Mammograms

For women with breast cancer aged 50 years or older and three years postdiagnosis, outcomes are no worse with less frequent mammograms than annual mammograms, a

Tardive Dyskinesia Impacts Patients and Caregivers

Tardive dyskinesia (TD) poses a substantial burden for both caregivers and patients, according to a study published online Nov. 28 in the Journal of Patient-Rep

FDA Approves Landmark Sickle Cell Gene Therapies, Casgevy and Lyfgenia

The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that